I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
Rhea-AI Summary
I-Mab (NASDAQ: IMAB) reported its full year 2024 financial results, highlighting progress in its givastomig Phase 1b combination trial for first-line gastric cancer. The company completed enrollment ahead of schedule in the first expansion cohort, with topline dose escalation data expected in 2H 2025.
Financial highlights include a strong cash position of $173.4 million as of December 31, 2024, providing runway into 2027. The company reported a net loss of $22.2 million for 2024, compared to $207.7 million in 2023. R&D expenses were $21.8 million, while administrative expenses reached $29.7 million.
Key developments include the completion of Greater China assets divestiture and business operations restructuring. The company is focusing on advancing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, with Phase 1b dose expansion study results expected in 1H 2026.
Positive
- Significant improvement in net loss to $22.2M in 2024 from $207.7M in 2023
- Strong cash position of $173.4M providing runway into 2027
- Ahead of schedule enrollment completion in first givastomig Phase 1b dose expansion cohort
- Successful completion of Greater China assets divestiture, resulting in $34.4M gain
Negative
- Increased administrative expenses to $29.7M from $28.2M YoY
- Higher R&D expenses at $21.8M compared to $21.4M in 2023
- Decreased interest income to $7.5M from $9.3M YoY
News Market Reaction 1 Alert
On the day this news was published, IMAB declined 6.86%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025
- Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohort
- Strong financial position supported by
$173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig
ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and business updates.
“The last year has been transformational for I-Mab. We successfully established a new model as a U.S.-based biotech company, divested all business operations in China, redefined our strategy, strengthened our leadership team, reprioritized our pipeline and accelerated the development of our lead program, givastomig, a novel Claudin-18.2 targeted therapy,” said Sean Fu, PhD, MBA, CEO and board member of I-Mab. “We believe givastomig is uniquely situated to be a potential best-in-class, Claudin-18.2 therapy, with broad applicability in gastric cancer and beyond, and our strong cash balance positions us to build on the momentum.”
2024 Selected Finance and Corporate Development Highlights:
- Appointment of Sean (Xi-Yong) Fu, PhD, MBA, as Chief Executive Officer.
- Completed divestiture of Greater China assets and business operations, including settlement of all non-participating shareholder redemption obligations.
Pipeline Overview and Potential Upcoming Milestones
In January 2025, the Company announced a portfolio re-prioritization, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line (1L) metastatic gastric cancers, with further potential in other solid tumors. The Company continues to monitor development of uliledlimab, an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment, in Phase 2 studies with its partner, TJ Biopharma, and support ongoing studies underway with its partner, ABL Bio, for ragistomig, a bispecific, Fc-silent antibody designed to provide anti-PD-L1 activity and conditional 4-1BB-driven T-cell activation in one molecule.
Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for 1L metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain a strong tumor-binding property and promising anti-tumor activity, attributable to a potential synergistic effect of proximal interaction between CLDN18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
Enrollment recently completed in the first dose expansion cohort (n=20), ahead of schedule, with continued momentum in the second dose expansion cohort (n=20). The Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy. The study builds on positive Phase 1 monotherapy data.
Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
Upcoming Phase 1b Givastomig Milestones:
- 2H 2025: Phase 1b dose escalation data (n=17) expected to be presented at a medical meeting.
- 1H 2026: Expected topline results from the ongoing dose expansion study (n=40).
Full Year 2024 Financial Results
Cash Position
As of December 31, 2024, the Company had cash, cash equivalents, and short-term investments of
Shares Outstanding
As of December 31, 2024, the Company had 187,452,495 ordinary shares issued and outstanding, representing the equivalent of 81,501,085 ADSs, assuming the conversion of all ordinary shares into ADSs.
Research & Development Expenses
Research and development expenses were
Administrative Expenses
Administrative expenses were
Interest Income
Interest income was
Other Expenses, Net
Other expenses, net were
Equity in Loss of Affiliates
Equity in loss of affiliates was
Net Loss from Continuing Operations
Net loss from continuing operations was
Net Loss from Discontinued Operations
On April 2, 2024, the Company closed the China divestiture announced on February 7, 2024 (the “Transaction”). The Company determined that the Transaction represented a strategic shift that had a major effect on the business and therefore, met the criteria for classification as discontinued operations at December 31, 2024. Accordingly, the carrying value of in-process research and development and the net assets associated with the Greater China business operations are reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations. Amounts applicable to prior years have been recast to conform to the discontinued operations presentation. The Company recognized a gain on the Transaction in the amount of
Net Loss
Net loss was
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
Exchange Rate Information
As part of I-Mab’s strategic transition to a U.S.-based biotech, effective April 2, 2024, the Company changed its reporting currency from RMB to USD. As indicated in its interim financial results, reported on August 28, 2024, the Company applied this change retrospectively to its historical results of operations and financial statements, as if the Company had always used the U.S. dollar as its reporting currency.
I-Mab Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s pipeline and clinical development of I-Mab’s drug candidates, including givastomig; the projected advancement of the Company’s portfolio and anticipated milestones and related timing; the Company’s expectations regarding the impact of data from ongoing and future clinical trials; the Company’s expectations regarding its cash runway; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the “Risk Factors” section in I-Mab’s annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
I-Mab Investor & Media Contacts
| PJ Kelleher | |
| LifeSci Advisors | |
| +1-617-430-7579 | |
| pkelleher@lifesciadvisors.com | |
| IR@imabbio.com |
| I-Mab | |||||||
| Consolidated Balance Sheets | |||||||
| (All amounts in thousands, except for share data) | |||||||
| As of December 31, | |||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 68,263 | $ | 291,506 | |||
| Short-term investments | 105,135 | 20,221 | |||||
| Prepayments and other receivables | 3,295 | 2,503 | |||||
| Current assets of discontinued operations | — | 15,682 | |||||
| Total current assets | 176,693 | 329,912 | |||||
| Property, equipment and software | 201 | 1,777 | |||||
| Operating lease right-of-use assets | 3,597 | 3,777 | |||||
| Investments at fair value, available-for-sale debt securities (amortized cost of | 30,824 | — | |||||
| Other non-current assets | 1,365 | 248 | |||||
| Non-current assets of discontinued operations | — | 33,208 | |||||
| Total assets | $ | 212,680 | $ | 368,922 | |||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities | |||||||
| Accruals and other payables | $ | 7,638 | $ | 7,849 | |||
| Operating lease liabilities, current | 816 | 626 | |||||
| Current liabilities of discontinued operations | — | 49,669 | |||||
| Total current liabilities | 8,454 | 58,144 | |||||
| Put right liabilities, non-current | — | 13,852 | |||||
| Operating lease liabilities, non-current | 3,066 | 3,261 | |||||
| Other non-current liabilities | — | 106 | |||||
| Non-current liabilities of discontinued operations | — | 50,975 | |||||
| Total liabilities | 11,520 | 126,338 | |||||
| Commitments and contingencies | |||||||
| Shareholders’ equity | |||||||
| Ordinary shares ( December 31, 2024 and 2023; 187,452,495 and 185,613,662 shares issued and outstanding as of December 31, 2024 and 2023, respectively) | 19 | 19 | |||||
| Treasury stock | (6,225 | ) | (8,007 | ) | |||
| Additional paid-in capital | 1,460,021 | 1,474,610 | |||||
| Accumulated other comprehensive income | 33,384 | 39,771 | |||||
| Accumulated deficit | (1,286,039 | ) | (1,263,809 | ) | |||
| Total shareholders’ equity | 201,160 | 242,584 | |||||
| Total liabilities and shareholders’ equity | $ | 212,680 | $ | 368,922 | |||
| I-Mab | |||||||||||
| Consolidated Statements of Comprehensive Loss | |||||||||||
| (All amounts in thousands, except for share and per share data) | |||||||||||
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | 2022 | |||||||||
| Revenues | |||||||||||
| Licensing and collaboration revenue | $ | — | $ | 632 | $ | (1,551 | ) | ||||
| Total revenues | — | 632 | (1,551 | ) | |||||||
| Expenses | |||||||||||
| Research and development expenses(1) | (21,770 | ) | (21,448 | ) | (22,547 | ) | |||||
| Administrative expenses(2) | (29,656 | ) | (28,160 | ) | (28,980 | ) | |||||
| Impairment of goodwill | — | (23,041 | ) | — | |||||||
| Total expenses | (51,426 | ) | (72,649 | ) | (51,527 | ) | |||||
| Loss from operations | (51,426 | ) | (72,017 | ) | (53,078 | ) | |||||
| Interest income | 7,486 | 9,294 | 4,954 | ||||||||
| Other expenses, net | (4,718 | ) | (8,090 | ) | (28,269 | ) | |||||
| Equity in loss of affiliates(3) | (1,038 | ) | (11,404 | ) | (64,707 | ) | |||||
| Loss from continuing operations before income tax expense | (49,696 | ) | (82,217 | ) | (141,100 | ) | |||||
| Income tax expense | — | — | (103 | ) | |||||||
| Loss from continuing operations | $ | (49,696 | ) | $ | (82,217 | ) | $ | (141,203 | ) | ||
| Discontinued operations: | |||||||||||
| Loss from operations of discontinued operations(4) | $ | (6,898 | ) | $ | (125,512 | ) | $ | (229,850 | ) | ||
| Income tax expense | — | — | — | ||||||||
| Gain on sale of discontinued operations | 34,364 | — | — | ||||||||
| Gain (loss) from discontinued operations | $ | 27,466 | $ | (125,512 | ) | $ | (229,850 | ) | |||
| Net loss | $ | (22,230 | ) | $ | (207,729 | ) | $ | (371,053 | ) | ||
| Other comprehensive income (loss): | |||||||||||
| Unrealized loss on available-for-sale debt securities, net of tax | $ | (8,168 | ) | $ | — | $ | — | ||||
| Foreign currency translation adjustments, net of tax | 1,781 | 5,605 | 5,587 | ||||||||
| Total comprehensive loss | $ | (28,617 | ) | $ | (202,124 | ) | $ | (365,466 | ) | ||
| Weighted-average number of ordinary shares used in calculating net loss per share - basic and diluted | 186,728,372 | 191,423,850 | 189,787,292 | ||||||||
| Net loss from continuing operations per share - basic and diluted | $ | (0.27 | ) | $ | (0.43 | ) | $ | (0.74 | ) | ||
| Net gain (loss) from discontinued operations per share - basic and diluted | $ | 0.15 | $ | (0.66 | ) | $ | (1.22 | ) | |||
| Net loss per share - basic and diluted | $ | (0.12 | ) | $ | (1.09 | ) | $ | (1.96 | ) | ||
| Net loss from continuing operations per ADS(5)- basic and diluted | $ | (0.61 | ) | $ | (0.99 | ) | $ | (1.71 | ) | ||
| Net gain (loss) from discontinued operations per ADS(5)- basic and diluted | $ | 0.34 | $ | (1.51 | ) | $ | (2.79 | ) | |||
| Net loss per ADS(5)- basic and diluted | $ | (0.27 | ) | $ | (2.50 | ) | $ | (4.50 | ) | ||
(1) Includes share-based compensation expense of
(2) Includes share-based compensation expense of
(3) Includes share-based compensation expense of
(4) Includes share-based compensation expense of
(5) Each 10 ADSs represents 23 ordinary shares.
| I-Mab | |||||||||||
| Consolidated Statements of Cash Flows | |||||||||||
| (All amounts in thousands) | |||||||||||
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | 2022 | |||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (22,230 | ) | $ | (207,729 | ) | $ | (371,053 | ) | ||
| Less: net gain (loss) from discontinued operations | 27,466 | (125,512 | ) | (229,850 | ) | ||||||
| Net loss from continuing operations | (49,696 | ) | (82,217 | ) | (141,203 | ) | |||||
| Adjustments to reconcile net loss to net cash used in operating activities from continuing operations | |||||||||||
| Share-based compensation | (1,949 | ) | 10,239 | 13,149 | |||||||
| Change in fair value and extinguishment of put right liabilities | (13,852 | ) | 1,118 | (5,070 | ) | ||||||
| Equity in loss of affiliates | 1,038 | 11,404 | 64,707 | ||||||||
| Depreciation of property, equipment and software | 261 | 475 | 206 | ||||||||
| Impairment of goodwill | — | 23,041 | — | ||||||||
| Settlement of TJ Biopharma repurchase obligations | 12,388 | — | — | ||||||||
| Amortization of right-of use assets | 717 | 586 | 1,209 | ||||||||
| Impairment of fixed assets | 622 | — | — | ||||||||
| Impairment of assets held for sale | 624 | — | — | ||||||||
| Gain on disposal of property and equipment | (11 | ) | — | (27 | ) | ||||||
| Change in fair value of short-term and other investments | — | (221 | ) | (1,898 | ) | ||||||
| Recognition of deferred cost for planned dual listing | — | — | 2,253 | ||||||||
| Changes in operating assets and liabilities | |||||||||||
| Prepayments and other receivables | (1,904 | ) | 28 | (1,800 | ) | ||||||
| Accruals and other payables | (213 | ) | (35,681 | ) | 18,337 | ||||||
| Other non-current liabilities | (106 | ) | (894 | ) | 226 | ||||||
| Operating lease liability, net | (588 | ) | (575 | ) | (1,217 | ) | |||||
| Accounts receivable | — | — | (2,755 | ) | |||||||
| Contract assets | — | — | 4,301 | ||||||||
| Net cash used in operating activities from continuing operations | (52,669 | ) | (72,697 | ) | (49,582 | ) | |||||
| Cash flows from investing activities | |||||||||||
| Proceeds from disposal of short-term and other investments | 109,834 | 85,000 | 764,421 | ||||||||
| Purchase of short-term and other investments | (194,748 | ) | (100,000 | ) | (767,510 | ) | |||||
| Purchase of available-for-sale debt securities | (51,115 | ) | — | — | |||||||
| Purchase of property, equipment and software | (48 | ) | (164 | ) | (2,091 | ) | |||||
| Proceeds from disposal of property and equipment | 62 | — | — | ||||||||
| Net cash used in investing activities from continuing operations | (136,015 | ) | (15,164 | ) | (5,180 | ) | |||||
| Cash flows from financing activities | |||||||||||
| Payment for stock repurchases | (335 | ) | (8,644 | ) | (3,006 | ) | |||||
| Proceeds from exercise of stock options | — | 407 | 6,918 | ||||||||
| Net cash (used in) generated from financing activities from continuing operations | $ | (335 | ) | $ | (8,237 | ) | $ | 3,912 | |||
| I-Mab | |||||||||||
| Consolidated Statements of Cash Flows (continued) | |||||||||||
| (All amounts in thousands) | |||||||||||
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | 2022 | |||||||||
| Discontinued operations: | |||||||||||
| Net cash used in operating activities | $ | (27,498 | ) | $ | (109,791 | ) | $ | (116,663 | ) | ||
| Net cash (used in) generated from investing activities | (22,289 | ) | 26,077 | 73,216 | |||||||
| Net cash (used in) generated from financing activities | (4,171 | ) | 9,911 | 2,805 | |||||||
| Net cash used in discontinued operations | (53,958 | ) | (73,803 | ) | (40,642 | ) | |||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 573 | 5,197 | 14,197 | ||||||||
| Net decrease in cash and cash equivalents | (242,404 | ) | (164,704 | ) | (77,295 | ) | |||||
| Cash and cash equivalents, beginning of year | 310,667 | 475,371 | 552,666 | ||||||||
| Cash and cash equivalents, end of year | $ | 68,263 | $ | 310,667 | $ | 475,371 | |||||
| Additional ASC 842 supplemental disclosures | |||||||||||
| Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities | $ | 805 | $ | 739 | $ | 909 | |||||
| Right-of-use assets obtained in exchange for operating lease obligations | $ | 282 | $ | 1,426 | $ | — | |||||
| Other supplemental cash flow disclosures | |||||||||||
| Income tax paid | $ | — | $ | — | $ | 103 | |||||
| Interest paid | $ | — | $ | — | $ | — | |||||
| Non-cash activities | |||||||||||
| Payables for purchase of property, equipment and software | $ | — | $ | — | $ | 124 | |||||
| Unrealized loss on available-for-sale debt securities | $ | 8,168 | $ | — | $ | — | |||||
| The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated Balance Sheets: | |||||||||||
| Cash and cash equivalents | $ | 68,263 | $ | 291,506 | $ | 342,922 | |||||
| Restricted cash(1) | — | — | 5,000 | ||||||||
| Cash and cash equivalents in current assets of discontinued operations | — | 10,843 | 8,894 | ||||||||
| Restricted cash in non-current assets of discontinued operations | — | 8,318 | 118,555 | ||||||||
| Total cash and cash equivalents and restricted cash | $ | 68,263 | $ | 310,667 | $ | 475,371 | |||||
(1) The
FAQ
What are the key milestones for IMAB's givastomig trial in 2025-2026?
How much cash does IMAB have and how long will it last?
What was IMAB's net loss for full year 2024?
What is the status of IMAB's givastomig Phase 1b trial enrollment?
